CTK’s goal during the current COVID-19 pandemic is to provide quality diagnostic tools for the detection of SARS-CoV-2, such as the Aridia Real-Time COVID-19 PCR Test. As new SARS-CoV-2 variants are identified, CTK has been working on confirmation studies to ensure that the performance of the Aridia COVID-19 Real-Time PCR Test isn’t affected by these mutations.
The Aridia COVID-19 Real-Time PCR Test is designed for the specific and qualitative detection of the novel coronavirus SARS-CoV-2, responsible for COVID-19, in respiratory specimens. The test targets the conserved regions of the SARS-CoV-2 ORF1ab and N genes using specific primers and fluorescently labeled probes.
We performed both wet testing and in silico assessments (computer simulations) of the sequence of genetic variants of the SARS-CoV-2 virus relative to the sequences of the primers and probes used in the Aridia COVID-19 Real-Time PCR Test. Based on these studies, the test can detect the SARS-CoV-2 U.K., South Africa, Brazil, California, Nigeria, and India (delta) variants. Furthermore, as the Aridia COVID-19 Real-Time PCR Test detects two Sars-CoV-2 targets, its performance is less susceptible to the effects of variants than tests designed to detect a single target.
To read the whitepaper, click here
Zhong, L, Zhang, L, Liberal, V. (2021). Aridia COVID-19 Real-Time PCR Tests detect new SARS-CoV-2 variants, including U.K., South Africa, Brazil, California, Nigeria, and India/Delta variants [White paper]. CTK Biotech.